Bolder BioPATH, Inc., an Inotiv company, is a contract pharmacology and pathology company specializing in in vivo models of Rheumatoid Arthritis, Osteoarthritis, and Inflammatory Bowel Disease as well as other autoimmune and inflammation models. Our goals are to provide preclinical (efficacy and toxicity) data to support advancing proteins and small molecules to IND/NDA stage.
“At Bolder BioPATH, our mission has been to always deliver exceptional service and provide clients with the highest quality data to help them move quickly toward key decisions.”Alison Bendele, founder and President of Bolder BioPATH
To learn more about the acquisition, read our news release.
To talk to an expert about our services, please click here.
Established Pharmacology and Toxicology Models
Access a wide range of in vivo preclinical early-stage research, efficacy, pharmacology, and safety studies. Our experienced staff has the expertise to offer a wide range of study designs in pharmacology, toxicology, inflammatory bowel disease, and immunologic models. Our hands-on collaborative approach means that our scientists will work with you to learn your specific preclinical study requirements and assist you from initial study design to final reporting with dependable, reproducible results.